Cargando…

A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults

Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against S...

Descripción completa

Detalles Bibliográficos
Autores principales: Meron-Sudai, Shiri, Asato, Valeria, Adler, Amos, Bialik, Anya, Goren, Sophy, Ariel-Cohen, Ortal, Reizis, Arava, Mulard, Laurence A., Phalipon, Armelle, Cohen, Dani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998260/
https://www.ncbi.nlm.nih.gov/pubmed/36894570
http://dx.doi.org/10.1038/s41541-023-00624-y
_version_ 1784903436941131776
author Meron-Sudai, Shiri
Asato, Valeria
Adler, Amos
Bialik, Anya
Goren, Sophy
Ariel-Cohen, Ortal
Reizis, Arava
Mulard, Laurence A.
Phalipon, Armelle
Cohen, Dani
author_facet Meron-Sudai, Shiri
Asato, Valeria
Adler, Amos
Bialik, Anya
Goren, Sophy
Ariel-Cohen, Ortal
Reizis, Arava
Mulard, Laurence A.
Phalipon, Armelle
Cohen, Dani
author_sort Meron-Sudai, Shiri
collection PubMed
description Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.
format Online
Article
Text
id pubmed-9998260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99982602023-03-10 A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults Meron-Sudai, Shiri Asato, Valeria Adler, Amos Bialik, Anya Goren, Sophy Ariel-Cohen, Ortal Reizis, Arava Mulard, Laurence A. Phalipon, Armelle Cohen, Dani NPJ Vaccines Article Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate. Nature Publishing Group UK 2023-03-10 /pmc/articles/PMC9998260/ /pubmed/36894570 http://dx.doi.org/10.1038/s41541-023-00624-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Meron-Sudai, Shiri
Asato, Valeria
Adler, Amos
Bialik, Anya
Goren, Sophy
Ariel-Cohen, Ortal
Reizis, Arava
Mulard, Laurence A.
Phalipon, Armelle
Cohen, Dani
A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title_full A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title_fullStr A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title_full_unstemmed A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title_short A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
title_sort shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998260/
https://www.ncbi.nlm.nih.gov/pubmed/36894570
http://dx.doi.org/10.1038/s41541-023-00624-y
work_keys_str_mv AT meronsudaishiri ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT asatovaleria ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT adleramos ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT bialikanya ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT gorensophy ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT arielcohenortal ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT reizisarava ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT mulardlaurencea ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT phaliponarmelle ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT cohendani ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT meronsudaishiri shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT asatovaleria shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT adleramos shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT bialikanya shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT gorensophy shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT arielcohenortal shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT reizisarava shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT mulardlaurencea shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT phaliponarmelle shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults
AT cohendani shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults